Skip to main content
Top
Published in: Rheumatology International 4/2013

01-04-2013 | Review

The importance of rheumatology biologic registries in Latin America

Authors: Maria de la Vega, Hellen M. da Silveira de Carvalho, Lucio Ventura Ríos, Maria V. Goycochea Robles, Gustavo C. Casado

Published in: Rheumatology International | Issue 4/2013

Login to get access

Abstract

Rheumatoid arthritis is a systemic inflammatory disorder characterized by joint articular pain and disability. Although there is scarcity of data available on the incidence and prevalence of RA in Latin America, there is a growing recognition of this disease where chronic diseases are on the rise and infectious disease on the decline. RA is a substantial burden to patients, society, and the healthcare system. The heterogeneity identified within RA presents an opportunity for personalized medicine, especially in regions with such demographic diversity as that of Latin America. To understand the long-term effects of treatment for RA especially on safety, registries have been established, a number of which have been created in Latin America. Despite their weaknesses (e.g., lack of controls and randomization), registries have provided additional and complementary information on the use of biologics in clinical practice in Latin America and other regions. Although certain challenges remain in the implementation and maintenance of registries, they continue to provide real-life data to clinical practice contributing to improved patient care.
Literature
1.
go back to reference Harris ED Jr (1990) Rheumatoid arthritis. Pathophysiology and implications for therapy. N Engl J Med 322:1277–1289PubMedCrossRef Harris ED Jr (1990) Rheumatoid arthritis. Pathophysiology and implications for therapy. N Engl J Med 322:1277–1289PubMedCrossRef
2.
go back to reference Scublinsky D, Venarotti H, Citera G, Messina OD, Scheines E, Rillo O et al (2010) The prevalence of rheumatoid arthritis in Argentina: a capture–recapture study in a city in Buenos Aires province. J Clin Rheumatol 16:317–321PubMed Scublinsky D, Venarotti H, Citera G, Messina OD, Scheines E, Rillo O et al (2010) The prevalence of rheumatoid arthritis in Argentina: a capture–recapture study in a city in Buenos Aires province. J Clin Rheumatol 16:317–321PubMed
3.
go back to reference Reyes-Llerena GA, Guibert-Toledano M, Penedo-Coello A, Pérez-Rodríguez A, Baez-Dueñas RM, Charnicharo-Vidal R et al (2009) Community-based study to estimate prevalence and burden of illness of rheumatic diseases in Cuba: a COPCORD study. J Clin Rheum atol 15:51–55CrossRef Reyes-Llerena GA, Guibert-Toledano M, Penedo-Coello A, Pérez-Rodríguez A, Baez-Dueñas RM, Charnicharo-Vidal R et al (2009) Community-based study to estimate prevalence and burden of illness of rheumatic diseases in Cuba: a COPCORD study. J Clin Rheum atol 15:51–55CrossRef
4.
go back to reference Cardiel MH, Rojas-Serrano J (2002) Community based study to estimate prevalence, burden of illness and help seeking behavior in rheumatic diseases in Mexico City. A COPCORD study. Clin Exp Rheum 20:617–624 Cardiel MH, Rojas-Serrano J (2002) Community based study to estimate prevalence, burden of illness and help seeking behavior in rheumatic diseases in Mexico City. A COPCORD study. Clin Exp Rheum 20:617–624
5.
go back to reference Rodriguez-Amado J, Peláez-Ballestas I, Sanin LH, Esquivel-Valerio JA, Burgos-Vargas R, Pérez-Barbosa L et al (2011) Epidemiology of rheumatic diseases. A community-based study in urban and rural populations in the state of Nuevo Leon, Mexico. J Rheumatol Suppl 86:9–14PubMedCrossRef Rodriguez-Amado J, Peláez-Ballestas I, Sanin LH, Esquivel-Valerio JA, Burgos-Vargas R, Pérez-Barbosa L et al (2011) Epidemiology of rheumatic diseases. A community-based study in urban and rural populations in the state of Nuevo Leon, Mexico. J Rheumatol Suppl 86:9–14PubMedCrossRef
6.
go back to reference Peláez-Ballestas I, Sanin LH, Moreno-Montoya J, Alvarez-Nemegyei J, Burgos-Vargas R, Garza-Elizondo M et al (2011) Epidemiology of the rheumatic diseases in Mexico. A study of 5 regions based on the COPCORD methodology [published erratum appears in J Rheumatol 2011;Suppl 38:585]. J Rheumatol Suppl 86:3–8PubMedCrossRef Peláez-Ballestas I, Sanin LH, Moreno-Montoya J, Alvarez-Nemegyei J, Burgos-Vargas R, Garza-Elizondo M et al (2011) Epidemiology of the rheumatic diseases in Mexico. A study of 5 regions based on the COPCORD methodology [published erratum appears in J Rheumatol 2011;Suppl 38:585]. J Rheumatol Suppl 86:3–8PubMedCrossRef
7.
go back to reference Alvarez-Nemegyei J, Peláez-Ballestas I, Sanin LH, Cardiel MH, Ramirez-Angulo A, Goycochea-Robles MV (2011) Prevalence of musculoskeletal pain and rheumatic diseases in the southeastern region of Mexico. A COPCORD-based community survey. J Rheumatol Suppl 86:21–25PubMedCrossRef Alvarez-Nemegyei J, Peláez-Ballestas I, Sanin LH, Cardiel MH, Ramirez-Angulo A, Goycochea-Robles MV (2011) Prevalence of musculoskeletal pain and rheumatic diseases in the southeastern region of Mexico. A COPCORD-based community survey. J Rheumatol Suppl 86:21–25PubMedCrossRef
8.
go back to reference Cardiel MH (2006) First Latin American position paper on the pharmacological treatment of rheumatoid arthritis. Rheumatology (Oxford) 45(Suppl. 2):ii7–ii22 Cardiel MH (2006) First Latin American position paper on the pharmacological treatment of rheumatoid arthritis. Rheumatology (Oxford) 45(Suppl. 2):ii7–ii22
10.
go back to reference Boonen A, Severens JL (2011) The burden of illness of rheumatoid arthritis. Clin Rheumatol 30(Suppl. 1):S3–S8PubMedCrossRef Boonen A, Severens JL (2011) The burden of illness of rheumatoid arthritis. Clin Rheumatol 30(Suppl. 1):S3–S8PubMedCrossRef
11.
go back to reference Morales-Romero J, Gonzalez-Lopez L, Celis A, Rodriguez-Arreola BE, Cabrera-Pivaral CE, Gamez-Nava JI (2006) Factors associated with permanent work disability in Mexican patients with rheumatoid arthritis. J Rheumatol 33:1247–1249PubMed Morales-Romero J, Gonzalez-Lopez L, Celis A, Rodriguez-Arreola BE, Cabrera-Pivaral CE, Gamez-Nava JI (2006) Factors associated with permanent work disability in Mexican patients with rheumatoid arthritis. J Rheumatol 33:1247–1249PubMed
12.
go back to reference Mould-Quevedo J, Peláez-Ballestas I, Vázquez-Mellado J, Terán-Estrada L, Esquivel-Valerio J, Ventura-Ríos L et al (2008) El costo de las principales enfermedades reumáticas inflamatorias desde la perspectiva del paciente en México. Gac Méd Méx 144:225–231PubMed Mould-Quevedo J, Peláez-Ballestas I, Vázquez-Mellado J, Terán-Estrada L, Esquivel-Valerio J, Ventura-Ríos L et al (2008) El costo de las principales enfermedades reumáticas inflamatorias desde la perspectiva del paciente en México. Gac Méd Méx 144:225–231PubMed
13.
go back to reference Curtis JR, Jain A, Askling J, Bridges SL Jr, Carmona L, Dixon W et al (2010) A comparison of patient characteristics and outcomes in selected European and US rheumatoid arthritis registries. Semin Arthritis Rheum 40:2–14.e1PubMedCrossRef Curtis JR, Jain A, Askling J, Bridges SL Jr, Carmona L, Dixon W et al (2010) A comparison of patient characteristics and outcomes in selected European and US rheumatoid arthritis registries. Semin Arthritis Rheum 40:2–14.e1PubMedCrossRef
14.
go back to reference Geborek P, Crnkic M, Peterson IF, Saxne T, on behalf of the South Swedish Arthritis Treatment Group (2002) Etanercept, infliximab, and leflunomide in established rheumatoid arthritis. Clinical experience using a structured follow-up programme in southern Sweden. Ann Rheum Dis 61:793–798PubMedCrossRef Geborek P, Crnkic M, Peterson IF, Saxne T, on behalf of the South Swedish Arthritis Treatment Group (2002) Etanercept, infliximab, and leflunomide in established rheumatoid arthritis. Clinical experience using a structured follow-up programme in southern Sweden. Ann Rheum Dis 61:793–798PubMedCrossRef
15.
go back to reference Silman A, Klareskog L, Breedveld F, Bresnihan B, Maini R, Van Riel P et al (2000) Proposal to establish a register for the long term surveillance of adverse events in patients with rheumatic diseases exposed to biological agents: the EULAR surveillance Register for Biological Compounds. Ann Rheum Dis 59:419–420PubMedCrossRef Silman A, Klareskog L, Breedveld F, Bresnihan B, Maini R, Van Riel P et al (2000) Proposal to establish a register for the long term surveillance of adverse events in patients with rheumatic diseases exposed to biological agents: the EULAR surveillance Register for Biological Compounds. Ann Rheum Dis 59:419–420PubMedCrossRef
16.
go back to reference Kremer JM, Gibofsky A, Greenberg JD (2008) The role of drug and disease registries in rheumatic disease epidemiology. Curr Opin Rheumatol 20:123–130PubMedCrossRef Kremer JM, Gibofsky A, Greenberg JD (2008) The role of drug and disease registries in rheumatic disease epidemiology. Curr Opin Rheumatol 20:123–130PubMedCrossRef
17.
go back to reference Gomez-Reino JJ, Carmona L, Descalzo MA (2007) Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection. Arthritis Rheum 57:756–761PubMedCrossRef Gomez-Reino JJ, Carmona L, Descalzo MA (2007) Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection. Arthritis Rheum 57:756–761PubMedCrossRef
18.
go back to reference Mariette X, Matucci-Cerinic M, Pavelka K, Taylor P, van Vollenhoven R, Heatley R et al (2011) Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis. Ann Rheum Dis 70:1895–1904PubMedCrossRef Mariette X, Matucci-Cerinic M, Pavelka K, Taylor P, van Vollenhoven R, Heatley R et al (2011) Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis. Ann Rheum Dis 70:1895–1904PubMedCrossRef
19.
go back to reference Verstappen SMM, King Y, Watson KD, Symmons DP, Hyrich KL, on behalf of the BSRBR Control Centre Consortium, BSR Biologics Register (2011) Anti-TNF therapies and pregnancy: outcome of 130 pregnancies in the British Society for Rheumatology Biologics Register. Ann Rheum Dis 70:823–826PubMedCrossRef Verstappen SMM, King Y, Watson KD, Symmons DP, Hyrich KL, on behalf of the BSRBR Control Centre Consortium, BSR Biologics Register (2011) Anti-TNF therapies and pregnancy: outcome of 130 pregnancies in the British Society for Rheumatology Biologics Register. Ann Rheum Dis 70:823–826PubMedCrossRef
20.
go back to reference Strangfeld A, Listing J, Rau R, Schneider M, Hierse F, Krause A, et al (2007) Pregnancy outcome after exposure to biologics: results from the German Biologics Register RABBIT [abstract]. Presented at the American College of Rheumatology 71st National Meeting, Boston, MA, USA, November 6–11, 2007 Strangfeld A, Listing J, Rau R, Schneider M, Hierse F, Krause A, et al (2007) Pregnancy outcome after exposure to biologics: results from the German Biologics Register RABBIT [abstract]. Presented at the American College of Rheumatology 71st National Meeting, Boston, MA, USA, November 6–11, 2007
21.
go back to reference Van Vollenhoven RF, Askling J (2005) Rheumatoid arthritis registries in Sweden. Clin Exp Rheumatol 23(Suppl 39):s195–s200PubMed Van Vollenhoven RF, Askling J (2005) Rheumatoid arthritis registries in Sweden. Clin Exp Rheumatol 23(Suppl 39):s195–s200PubMed
22.
go back to reference Galloway JB, Hyrich KL, Mercer LK, Dixon WG, Fu B, Ustianowski AP et al (2011) Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: update results from the British society for rheumatology biologics register with special emphasis on risks in the elderly. Rheumatology (Oxford) 50:124–131CrossRef Galloway JB, Hyrich KL, Mercer LK, Dixon WG, Fu B, Ustianowski AP et al (2011) Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: update results from the British society for rheumatology biologics register with special emphasis on risks in the elderly. Rheumatology (Oxford) 50:124–131CrossRef
23.
go back to reference Dixon WG, Hyrich KL, Watson KD, Lunt M, Galloway J, Ustianowski A et al (2010) Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British society for rheumatology biologics register (BSRBR). Ann Rheum Dis 69:522–528PubMedCrossRef Dixon WG, Hyrich KL, Watson KD, Lunt M, Galloway J, Ustianowski A et al (2010) Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British society for rheumatology biologics register (BSRBR). Ann Rheum Dis 69:522–528PubMedCrossRef
24.
go back to reference Strangfield A, Hierse F, Rau R, Burmester GR, Krummel-Lorenz B, Demary W et al (2010) Risk of incidence or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBIT. Arthritis Res Ther 12:R5CrossRef Strangfield A, Hierse F, Rau R, Burmester GR, Krummel-Lorenz B, Demary W et al (2010) Risk of incidence or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBIT. Arthritis Res Ther 12:R5CrossRef
25.
go back to reference Strangfeld A, Herse F, Kekow J, von Hinueber U, Tony HP, Dockhorn R et al (2009) Comparative effectiveness of tumour necrosis alpha inhibitors in combination with either methotrexate or leflunomide. Ann Rheum Dis 68:1856–1862PubMedCrossRef Strangfeld A, Herse F, Kekow J, von Hinueber U, Tony HP, Dockhorn R et al (2009) Comparative effectiveness of tumour necrosis alpha inhibitors in combination with either methotrexate or leflunomide. Ann Rheum Dis 68:1856–1862PubMedCrossRef
28.
go back to reference de la Vega M, Casado G, Citera G, Soriano E, Venarotti H, Saurit V et al (2011) Primer reporte de efectos adversos de tratamientos biológicos en Argentina. Informe de Registro BIOBADASAR. Rev Arg Reumatol 22:40–54 de la Vega M, Casado G, Citera G, Soriano E, Venarotti H, Saurit V et al (2011) Primer reporte de efectos adversos de tratamientos biológicos en Argentina. Informe de Registro BIOBADASAR. Rev Arg Reumatol 22:40–54
29.
go back to reference Titton DC, Silveira IG, Louzada-Junior P, Hayata AL, Carvalho HM, Ranza R et al (2011) Brazilian biologic registry: BIOBADABRASIL implementation process and preliminary process and preliminary results. Rev Bras Reumatol 51:145–160 Titton DC, Silveira IG, Louzada-Junior P, Hayata AL, Carvalho HM, Ranza R et al (2011) Brazilian biologic registry: BIOBADABRASIL implementation process and preliminary process and preliminary results. Rev Bras Reumatol 51:145–160
30.
go back to reference Titton DC (2011) BIOBADABRASIL: Brazilian biologic registry [editorial]. Rev Bras Reumatol 51:109–112 Titton DC (2011) BIOBADABRASIL: Brazilian biologic registry [editorial]. Rev Bras Reumatol 51:109–112
32.
go back to reference Titton D, Hayata A, Carvalho H, Silveira I, Miranda J, Rezende L et al (2010) Biologic register in a developing country: safety is different from European registries? The BIOBADABRASIL first results. Ann Rheum Dis 69(Suppl. 3):717 Titton D, Hayata A, Carvalho H, Silveira I, Miranda J, Rezende L et al (2010) Biologic register in a developing country: safety is different from European registries? The BIOBADABRASIL first results. Ann Rheum Dis 69(Suppl. 3):717
33.
go back to reference Ventura L, García M, Bernard G, Terán Estrada L, Castro N, Robles San Román M et al (2011) Prevalencia de infecciones virales en pacientes tratados con terapia biológica [Abstract 325]. Reumatol Clin 7(Suppl. 1):63–64 Ventura L, García M, Bernard G, Terán Estrada L, Castro N, Robles San Román M et al (2011) Prevalencia de infecciones virales en pacientes tratados con terapia biológica [Abstract 325]. Reumatol Clin 7(Suppl. 1):63–64
34.
go back to reference Ventura L, Garcia M, Bañuelos D, Saavedra M, Irazoque F, Meléndez C et al (2010) Adverse events and survival rate of biological therapy (TxB) in rheumatic disease BIOBADAMEX national register report. Rev Chil Reumatol 26:77 Ventura L, Garcia M, Bañuelos D, Saavedra M, Irazoque F, Meléndez C et al (2010) Adverse events and survival rate of biological therapy (TxB) in rheumatic disease BIOBADAMEX national register report. Rev Chil Reumatol 26:77
36.
go back to reference Ventura L, García de la Peña M, Bañuelos-Ramirez D, Saavedra-Salinas MA, Irazoque-Palazuelos F, Meléndez-Mercado CI et al (2010) Eventos adversos y tasa de sobrevida asociados a la terapia biológica (TxB) en padecimientos reumáticos. Reporte del Registro Nacional BIOBADAMEX [Abstract S-44]. Reumatol Clin 6(Suppl 1):28 Ventura L, García de la Peña M, Bañuelos-Ramirez D, Saavedra-Salinas MA, Irazoque-Palazuelos F, Meléndez-Mercado CI et al (2010) Eventos adversos y tasa de sobrevida asociados a la terapia biológica (TxB) en padecimientos reumáticos. Reporte del Registro Nacional BIOBADAMEX [Abstract S-44]. Reumatol Clin 6(Suppl 1):28
38.
go back to reference Symmons DP (2005) Looking back: rheumatoid arthritis—aetiology, occurrence and mortality. Rheumatology (Oxford) 44(Suppl 4):iv14–iv17 Symmons DP (2005) Looking back: rheumatoid arthritis—aetiology, occurrence and mortality. Rheumatology (Oxford) 44(Suppl 4):iv14–iv17
39.
go back to reference Ramos-Remus C, Sierra-Jimenez G, Skeith K, Aceves-Avila FJ, Russell AS, Offer R et al (2007) Latitude gradient influences the age of onset of rheumatoid arthritis patients. Clin Rheumatol 26:1725–1728PubMedCrossRef Ramos-Remus C, Sierra-Jimenez G, Skeith K, Aceves-Avila FJ, Russell AS, Offer R et al (2007) Latitude gradient influences the age of onset of rheumatoid arthritis patients. Clin Rheumatol 26:1725–1728PubMedCrossRef
40.
go back to reference Spindler A, Bellomio V, Berman A, Lucero E, Baigorria M, Paz S et al (2002) Prevalence of rheumatoid arthritis in Tucuman, Argentina. J Rheumatol 29:1166–1170PubMed Spindler A, Bellomio V, Berman A, Lucero E, Baigorria M, Paz S et al (2002) Prevalence of rheumatoid arthritis in Tucuman, Argentina. J Rheumatol 29:1166–1170PubMed
41.
go back to reference Senna ER, De Barros AL, Silva EO, Costa IF, Pereira LV, Ciconelli RM et al (2004) Prevalence of rheumatic diseases in Brazil: a study using the COPCORD approach. J Rheumatol 31:594–597PubMed Senna ER, De Barros AL, Silva EO, Costa IF, Pereira LV, Ciconelli RM et al (2004) Prevalence of rheumatic diseases in Brazil: a study using the COPCORD approach. J Rheumatol 31:594–597PubMed
42.
go back to reference Carmona L, on behalf of the Grupo de Estudio BIOBADASER (2009) Actualización de BIOBADASER. Reumatol Clin 5:66–70PubMedCrossRef Carmona L, on behalf of the Grupo de Estudio BIOBADASER (2009) Actualización de BIOBADASER. Reumatol Clin 5:66–70PubMedCrossRef
43.
go back to reference Neovius M, Simard JF, Klarescog L, Askling J, on behalf of the ARTIS Study Group (2011) Sick leave and disability pension before and after initiation of antirheumatic therapies in clinical practice. Ann Rheum Dis 70:1407–1414PubMedCrossRef Neovius M, Simard JF, Klarescog L, Askling J, on behalf of the ARTIS Study Group (2011) Sick leave and disability pension before and after initiation of antirheumatic therapies in clinical practice. Ann Rheum Dis 70:1407–1414PubMedCrossRef
44.
go back to reference Söderlin MK, Geborek P (2008) Changing pattern in the prescription of biological treatment in rheumatoid arthritis. A 7-year follow-up of 1,839 patients in southern Sweden. Ann Rheum Dis 67:37–42PubMedCrossRef Söderlin MK, Geborek P (2008) Changing pattern in the prescription of biological treatment in rheumatoid arthritis. A 7-year follow-up of 1,839 patients in southern Sweden. Ann Rheum Dis 67:37–42PubMedCrossRef
45.
go back to reference Louzada-Júnior P, Freitas MV, Oliveira RD, Deghaide NH, Conde RA, Bertolo MB et al (2008) A majority of Brazilian patients with rheumatoid arthritis HLA-DRB1 alleles carry both the HLA-DRB1 shared epitope and anti-citrullinated peptide antibodies. Braz J Med Biol Res 41:493–499PubMedCrossRef Louzada-Júnior P, Freitas MV, Oliveira RD, Deghaide NH, Conde RA, Bertolo MB et al (2008) A majority of Brazilian patients with rheumatoid arthritis HLA-DRB1 alleles carry both the HLA-DRB1 shared epitope and anti-citrullinated peptide antibodies. Braz J Med Biol Res 41:493–499PubMedCrossRef
46.
go back to reference Hetland ML, Christensen IJ, Tarp U, Dreyer L, Hansen A, Hansen IT et al (2010) Direct comparison of treatment responses, remission rates, and drug surveillance in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from 8 years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Arthritis Rheum 62:22–32PubMedCrossRef Hetland ML, Christensen IJ, Tarp U, Dreyer L, Hansen A, Hansen IT et al (2010) Direct comparison of treatment responses, remission rates, and drug surveillance in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from 8 years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Arthritis Rheum 62:22–32PubMedCrossRef
47.
go back to reference Gottenberg JE, Ravaud P, Bardin T, Cacoub P, Cantagrel A, Combe B et al (2010) Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry. Arthritis Rheum 62:2625–2632PubMedCrossRef Gottenberg JE, Ravaud P, Bardin T, Cacoub P, Cantagrel A, Combe B et al (2010) Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry. Arthritis Rheum 62:2625–2632PubMedCrossRef
48.
go back to reference Miossec P, Verweij CL, Klarescog L, Pitzalis C, Barton A, Lekkerkerker F et al (2011) Biomarkers and personalized medicine in rheumatoid arthritis: a proposal for interactions between academia, industry and regulatory bodies. Ann Rheum Dis 70:1713–1718PubMedCrossRef Miossec P, Verweij CL, Klarescog L, Pitzalis C, Barton A, Lekkerkerker F et al (2011) Biomarkers and personalized medicine in rheumatoid arthritis: a proposal for interactions between academia, industry and regulatory bodies. Ann Rheum Dis 70:1713–1718PubMedCrossRef
49.
go back to reference Strangfeld A, Eveslage M, Schneider M, Bergerhausen HJ, Klopsch T, Zink A et al (2011) Treatment benefit or survival of the fittest: what drives the time dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient? Ann Rheum Dis 70:1914–1920PubMedCrossRef Strangfeld A, Eveslage M, Schneider M, Bergerhausen HJ, Klopsch T, Zink A et al (2011) Treatment benefit or survival of the fittest: what drives the time dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient? Ann Rheum Dis 70:1914–1920PubMedCrossRef
50.
go back to reference Hyrich K, Symmons D, Watson K, Silman A, on behalf of the BSRBR Control Centre Consortium (2006) British Society for Rheumatology Biologics Register. Baseline comorbidity levels in biologic and standard DMARD treated patients with rheumatoid arthritis: results from a national patient register. Ann Rheum Dis 65:895–898PubMedCrossRef Hyrich K, Symmons D, Watson K, Silman A, on behalf of the BSRBR Control Centre Consortium (2006) British Society for Rheumatology Biologics Register. Baseline comorbidity levels in biologic and standard DMARD treated patients with rheumatoid arthritis: results from a national patient register. Ann Rheum Dis 65:895–898PubMedCrossRef
51.
go back to reference Greenberg JB, Reed G, Kremer JM, Tindall E, Kavanaugh A, Zheng C et al (2010) Association of methotrexate and tumour necrosis factor antagonists with risk of infectious outcomes including opportunistic infections in the CORRONA registry. Ann Rheum Dis 69:380–386PubMedCrossRef Greenberg JB, Reed G, Kremer JM, Tindall E, Kavanaugh A, Zheng C et al (2010) Association of methotrexate and tumour necrosis factor antagonists with risk of infectious outcomes including opportunistic infections in the CORRONA registry. Ann Rheum Dis 69:380–386PubMedCrossRef
52.
go back to reference Descalzo MA, Carmona L, on behalf of the Grupo de Estudio BIOBADASER (2010) BIOBADASER 2.0: análisis y tendencias en 2009. Reumatol Clin 6:240–243PubMedCrossRef Descalzo MA, Carmona L, on behalf of the Grupo de Estudio BIOBADASER (2010) BIOBADASER 2.0: análisis y tendencias en 2009. Reumatol Clin 6:240–243PubMedCrossRef
53.
go back to reference Carmona L, Gómez-Reino JJ, González-González R, en representación del Grupo de Estudio BIOBADASER (2005) Registro español de acontecimientos adversos de terapias biológicas en enfermedades reumáticas (BIOBADASER): informe de la situación a 14 de enero de 2005. Reumatol Clin 1:95–111PubMedCrossRef Carmona L, Gómez-Reino JJ, González-González R, en representación del Grupo de Estudio BIOBADASER (2005) Registro español de acontecimientos adversos de terapias biológicas en enfermedades reumáticas (BIOBADASER): informe de la situación a 14 de enero de 2005. Reumatol Clin 1:95–111PubMedCrossRef
54.
go back to reference Soliman M, Ashcroft DM, Watson KD, Lunt M, Symmons DP, Hyrich KL et al (2011) Impact of concomitant use of DMARDs on the persistence with anti-TNF therapies in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 70:583–589PubMedCrossRef Soliman M, Ashcroft DM, Watson KD, Lunt M, Symmons DP, Hyrich KL et al (2011) Impact of concomitant use of DMARDs on the persistence with anti-TNF therapies in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 70:583–589PubMedCrossRef
Metadata
Title
The importance of rheumatology biologic registries in Latin America
Authors
Maria de la Vega
Hellen M. da Silveira de Carvalho
Lucio Ventura Ríos
Maria V. Goycochea Robles
Gustavo C. Casado
Publication date
01-04-2013
Publisher
Springer-Verlag
Published in
Rheumatology International / Issue 4/2013
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-012-2610-2

Other articles of this Issue 4/2013

Rheumatology International 4/2013 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.